Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P09471: Variant p.Gly40Arg

Guanine nucleotide-binding protein G(o) subunit alpha
Gene: GNAO1
Feedback?
Variant information Variant position: help 40 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Arginine (R) at position 40 (G40R, p.Gly40Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In DEE17 and NEDIM. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 40 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 354 The length of the canonical sequence.
Location on the sequence: help EKNLKEDGISAAKDVKLLLL G AGESGKSTIVKQMKIIHEDG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         EKNLKEDGISAAKDVKLLLLGAGESGKSTIVKQMKIIHEDG

Mouse                         EKNLKEDGISAAKDVKLLLLGAGESGKSTIVKQMKIIHEDG

Rat                           EKNLKEDGISAAKDVKLLLLGAGESGKSTIVKQMKIIHEDG

Bovine                        EKNLKEDGISAAKDVKLLLLGAGESGKSTIVKQMKIIHEDG

Xenopus laevis                EKNLKEDGVTAAKDVKLLLLGAGESGKSTIVKQMKIIHEDG

Caenorhabditis elegans        EKNLKEDGMQAAKDIKLLLLGAGESGKSTIVKQMKIIHESG

Drosophila                    ERNLKEDGIQAAKDIKLLLLGAGESGKSTIVKQMKIIHESG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 354 Guanine nucleotide-binding protein G(o) subunit alpha
Domain 32 – 354 G-alpha
Region 35 – 48 G1 motif
Binding site 40 – 47
Binding site 47 – 47
Beta strand 34 – 45



Literature citations
Clinical whole-exome sequencing reveals a novel missense pathogenic variant of GNAO1 in a patient with infantile-onset epilepsy.
Law C.Y.; Chang S.T.; Cho S.Y.; Yau E.K.; Ng G.S.; Fong N.C.; Lam C.W.;
Clin. Chim. Acta 451:292-296(2015)
Cited for: VARIANT DEE17 ARG-40; GNAO1 encephalopathy: Broadening the phenotype and evaluating treatment and outcome.
Danti F.R.; Galosi S.; Romani M.; Montomoli M.; Carss K.J.; Raymond F.L.; Parrini E.; Bianchini C.; McShane T.; Dale R.C.; Mohammad S.S.; Shah U.; Mahant N.; Ng J.; McTague A.; Samanta R.; Vadlamani G.; Valente E.M.; Leuzzi V.; Kurian M.A.; Guerrini R.;
Neurol. Genet. 3:E143-E143(2017)
Cited for: VARIANTS NEDIM ARG-40; GLY-47; THR-56; CYS-209 AND GLY-246;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.